Compare LICN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LICN | SNTI |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 53.6M |
| IPO Year | 2023 | N/A |
| Metric | LICN | SNTI |
|---|---|---|
| Price | $3.03 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 9.1K | ★ 363.6K |
| Earning Date | 12-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,641,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.57 | $1.04 |
| 52 Week High | $33.64 | $5.10 |
| Indicator | LICN | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 35.19 |
| Support Level | $2.97 | $1.04 |
| Resistance Level | $3.12 | $1.16 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 37.10 | 0.00 |
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.